A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck

Conditions:   Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck;   Carcinoma, Squamous Cell of Head and Neck
Interventions:   Drug: Nivolumab and Ipilimumab;   Drug: Docetaxel
Sponsors:   AIO-Studien-gGmbH;   Bristol-Myers Squibb
Recruiting

https://ift.tt/2Mvu6sd